Rapid responders to frovatriptan in acute migraine treatment: Results from a long-term, open-label study

Pain Medicine

Volumn 10, Issue 4, 2009, Pages 633-638

  Spierings, Egilius L H ^a,b   Keywood, Charlotte ^a   Baggish, Jeffrey ^b   Blumenthal, Harvey J ^b   Cady, Roger K ^b   Cook, David H ^b   Diamond, Seymour ^b   Edwards, Keith R ^b   Friedgood, David L ^b   Gove, Ronald C ^b   Hier, Daniel B ^b   Kaniecki, Robert G ^b   Kudrow, David ^b   Lefton, Theodore E ^b   Logue, H Edward ^b   McIntosh, William E ^b   Menninger, W Walter ^b   Perse, Teri ^b   Porter, John A H ^b   Rapoport, Alan M ^b   Ryan, Robert E ^b   Sacco, Sara E ^b   Sadowsky, Carl H ^b   Saper, Joel R ^b   Schaerf, Frederick W ^b   Schecter, Jay A ^b   Schulman, Elliot A ^b   Silberstein, Stephen D ^b   Stark, Stuart R ^b   Stratton, Gus ^b   Tepper, Stewart J ^b   Tindel, Jerry ^b   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

Complete migraine relief; Frovatriptan; Headache freedom; Headache recurrence; Headache response; Migraine treatment; Rapid responders

Indexed keywords

FROVATRIPTAN; PLACEBO;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLUSHING; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; OPEN STUDY; PAIN ASSESSMENT; PARESTHESIA; RECURRENCE RISK; SIDE EFFECT; SOMNOLENCE; THORAX PAIN; THROAT TIGHTNESS;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CARBAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; RECURRENCE; SEROTONIN AGONISTS; TIME; TIME FACTORS; TREATMENT OUTCOME; TRYPTAMINES; YOUNG ADULT;

EID: 67049116490     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2009.00618.x     Document Type: Article

References (8)

1. Graul A, Leson P, Castaner J. SB-209509/VML-251. Drugs Future 1997;22:725-8.
2. 1D receptors. Eur J Pharmacol 1999;368:259-68.
3. 1D receptor antagonists and in situ hybridization. Cephalalgia 2002;22:83-93.
4. Buchan P, Keywood C, Wade A, Ward C. Clinical pharmacokinetics of frovatriptan. Headache 2002;42(suppl 2):S54-62.
5. 1B/1D-receptor ligand frovatriptan in human isolated basilar and coronary arteries. J Cardiovasc Pharmacol 1998;32:220-4.
6. Ryan RE, Géraud G, Goldstein J, Cady RK, Keywood C. The clinical efficacy of frovatriptan: Placebo-controlled studies. Headache 2002;42(suppl 2):S84-92.
7. International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):1-96.
8. Géraud G, Spierings ELH, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Headache 2002;42(suppl 2):S93-9.